Skip to Content

Posts tagged with "Diabetes and Obesity"

  • Diabetes and Obesity

    Speaking of Polyphenols. . .

    Yesterday’s mention of “nightmare polyphenols” prompted a reader to ask about the one in this paper. That’s it over there at the left, and yeah, that sure is a polyphenol. In fact, it’s a chaetochromin, a family of mycotoxins originally isolated from moldy rice. The paper doesn’t say anything about its stereochem… Read More
  • Biological News

    Ces3 (Ces1) Inhibition As a Drug Target

    Update: the nomenclature of these enzymes is messy – see the comments. Here’s another activity-based proteomics result that I’ve been meaning to link to – in this one, the Cravatt group strengthens the case for carboxylesterase 3 as a potential target for metabolic disease. From what I can see, that enzyme was first identifi… Read More
  • Biological News

    Irisin and Metabolism – A New Target Emerges

    Here’s something for metabolic disease people to think about: there’s a report adding to what we know about the hormone irisin, secreted from muscle tissue, that causes some depots of white adipose tissue to become more like energy-burning brown fat. In the late 1990s, there were efforts all across the drug industry to find beta-3… Read More
  • Aging and Lifespan

    Boost Your NAD And Fix It All?

    Here’s a paper from a few weeks back that I missed during the holidays: work from the Sinclair labs at Harvard showing a new connection between SIRT1 and aging, this time through a mechanism that no one had appreciated. I’ll appreciate, in turn, that that opening sentence is likely to divide its readers into those… Read More
  • Business and Markets

    Bristol-Myers Squibb Exits Diabetes

    As the Wall Street Journal reported last night, Bristol-Myers Squibb is getting out of the diabetes business entirely, selling its collaboration with AstraZeneca back to AZ. As part of the transaction, and subject to local consultation and legislation, Bristol-Myers Squibb and AstraZeneca anticipate that substantially all employees of Bristol-Myers… Read More
  • Clinical Trials

    Zafgen’s Epoxide Clears A Hurdle

    I wrote here about Zafgen and their covalent Met-Ap2 inhibitor beloranib. Word is out today that the compound has passed its first Phase II trial handily, so score one for covalent epoxides as drug candidates. Zafgen has followed up promising results from early-stage work on its weight drug beloranib with a stellar Phase II study… Read More
  • Business and Markets

    Exiting Two Therapeutic Areas

    So Bristol-Myers Squibb did indeed re-org itself yesterday, with the loss of about 75 jobs (and the shifting around of 300 more, which will probably result in some job losses as well, since not everyone is going to be able to do that). And they announced that they’re getting out of two therapeutic areas, diabetes… Read More
  • Clinical Trials

    Mannkind’s Latest Data

    I haven’t written much about Mannkind recently. This has been a long, long, expensive saga to develop an inhaled-insulin delivery system (Afrezza), which is an idea that all by itself has seems to have swallowed several billion dollars and never given anything back yet. (That link above will send you to some of the story… Read More
  • Clinical Trials

    The Last PPAR Compound?

    Roche has announced that they’re halting trials of aleglitazar, a long-running investigational drug in their diabetes portfolio. I’m noting this because I think that this might be the absolute last of the PPAR ligands to fail in the clinic. And boy howdy, has it been a long list. Merck, Lilly, Kyorin, Bristol-Myers Squibb, Novo Nordisk… Read More
  • Diabetes and Obesity

    Today’s Avandia Hearing at the FDA

    If you want to follow the blow-by-blow of today’s FDA hearing on the marketing restrictions on Avandia (rosiglitazone), I can send you to Matthew Herper’s Twitter feed. He has the goods. Read More
...345...